TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

Ke Gong, Gao Guo, David E. Gerber, Boning Gao, Michael Peyton, Chun Huang, John D. Minna, Kimmo J. Hatanpaa, Kemp Kernstine, Ling Cai, Yang Xie, Hong Zhu, Farjana J. Fattah, Shanrong Zhang, Masaya Takahashi, Bipasha Mukherjee, Sandeep Burma, Jonathan Dowell, Kathryn Dao, Vassiliki A. PapadimitrakopoulouVictor Olivas, Trever G. Bivona, Dawen Zhao, Amyn A. Habib

Producción científica: Articlerevisión exhaustiva

71 Citas (Scopus)

Resumen

Although aberrant EGFR signaling is widespread in cancer, EGFR inhibition is effective only in a subset of non-small cell lung cancer (NSCLC) with EGFR activating mutations. A majority of NSCLCs express EGFR wild type (EGFRwt) and do not respond to EGFR inhibition. TNF is a major mediator of inflammation-induced cancer. We find that a rapid increase in TNF level is a universal adaptive response to EGFR inhibition in NSCLC, regardless of EGFR status. EGFR signaling actively suppresses TNF mRNA levels by inducing expression of miR-21, resulting in decreased TNF mRNA stability. Conversely, EGFR inhibition results in loss of miR-21 and increased TNF mRNA stability. In addition, TNF-induced NF-?B activation leads to increased TNF transcription in a feed-forward loop. Inhibition of TNF signaling renders EGFRwt-expressing NSCLC cell lines and an EGFRwt patient-derived xenograft (PDX) model highly sensitive to EGFR inhibition. In EGFR-mutant oncogene-addicted cells, blocking TNF enhances the effectiveness of EGFR inhibition. EGFR plus TNF inhibition is also effective in NSCLC with acquired resistance to EGFR inhibition. We suggest concomitant EGFR and TNF inhibition as a potentially new treatment approach that could be beneficial for a majority of lung cancer patients.

Idioma originalEnglish (US)
Páginas (desde-hasta)2500-2518
Número de páginas19
PublicaciónJournal of Clinical Investigation
Volumen128
N.º6
DOI
EstadoPublished - jun 1 2018
Publicado de forma externa

ASJC Scopus subject areas

  • General Medicine

Huella

Profundice en los temas de investigación de 'TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer'. En conjunto forman una huella única.

Citar esto